Financial Performance - The company achieved a revenue of CNY 2.741 billion, a year-on-year decrease of 4.46% [3] - Net profit attributable to shareholders was CNY 196 million, an increase of 6.42% year-on-year, indicating stable core business operations [3] - The nuclear medicine segment generated sales of CNY 1.136 billion, up 12.21% year-on-year, with key product 18F-FDG contributing CNY 498 million, a growth of 18.35% [3] - The raw material drug segment reported sales of CNY 1.014 billion, down 19.19%, primarily due to a 22.17% decline in heparin product sales [3] - The formulation segment's sales reached CNY 359 million, a growth of 10.37%, with key product nadroparin calcium injection achieving CNY 157 million, up 22.78% [3] R&D Progress - Multiple innovative and generic drugs made significant breakthroughs, with three innovative nuclear drugs entering Phase II clinical trials and one in Phase III [3] - The NDA for 18F-FDG was submitted and accepted by the National Medical Products Administration on January 9, 2026 [3] - The company established a radioactive isotope development platform to address the shortage of medical isotopes, with strategic partnerships for the construction of a dedicated reactor project [5] Production Capacity - The company operates 31 nuclear medicine production centers, covering 93.5% of the domestic nuclear medicine demand [4] - Seven centers are under construction, enhancing the company's competitive edge in networked production [4] Market Strategy - The accessibility of 18F-FDG improved due to the optimized management and service quality, leading to increased sales [8] - The company is focusing on international collaborations to enhance its position in the medical isotope market [7] Future Outlook - The company plans to complete product qualification for 20 production centers by the end of 2026, enhancing its production capabilities [9] - The pricing trend for raw material heparin is expected to remain volatile, influenced by overall industry conditions [12] - The company is actively pursuing overseas business opportunities to leverage international expertise and standards [14]

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) announced that its subsidiary, Yantai Lannacheng Biotechnology Co., Ltd. (referred to as "Lannacheng"), has received the acceptance notice from the National Medical Products Administration for the marketing authorization application of the investigational drug Fluorine-18 [18F] PSMA peptide injection [1] Group 1 - Lannacheng's Fluorine-18 [18F] PSMA peptide injection is a targeted radioactive diagnostic drug for in vivo imaging of prostate cancer patients with positive prostate-specific membrane antigen (PSMA) lesions [1] - The drug is intended for two specific patient groups: (1) prostate cancer patients suspected of having metastatic lesions who are about to undergo initial radical treatment; (2) prostate cancer patients with elevated serum prostate-specific antigen (PSA) levels suspected of biochemical recurrence [1]

Core Viewpoint - Dongcheng Pharmaceutical's subsidiary, Lanacheng, has received approval from the National Medical Products Administration for the marketing application of the investigational drug Fluorine-18 [18F] PSMA peptide injection, which targets PSMA for PET imaging in prostate cancer patients [1] Group 1: Product Information - Fluorine-18 [18F] PSMA peptide injection is a radiopharmaceutical used for in vivo diagnostic imaging targeting prostate-specific membrane antigen (PSMA) in prostate cancer patients [1] - There are currently no similar products available in the domestic market, while similar products are already available internationally [1] Group 2: Market Context - Lantheus Holdings reported that its product, 18F-PSMA diagnostic agent PYLARIFY, is expected to generate sales revenue of $1.1 billion in 2024 [1]

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) has received a notice from the National Medical Products Administration regarding the acceptance of its application for the marketing authorization of Fluorine-18 PSMA peptide injection, a targeted radioactive diagnostic drug for prostate cancer patients [2] Group 1: Product Development - The drug is designed for PET imaging in prostate cancer patients and is the first of its kind to be approved for marketing in China, with similar products already available and performing well in international markets [2] - The company acknowledges the inherent uncertainties in new drug development and commits to actively advancing the subsequent processes while ensuring timely information disclosure [2]

Core Viewpoint - The company is making steady progress on its key products before the IPO, with specific timelines for NDA submissions for its investigational drugs [2] Group 1: Product Development Progress - The impurity supplement study for 18F-APN-1607 is ongoing, with no specific completion date mentioned [2] - The NDA for fluorine-18 labeled somatostatin analog (氟[18F]思睿肽) is expected to be submitted in the first half of 2026, while the NDA for fluorine-18 labeled alpha peptide (氟[18F]阿法肽) is anticipated in 2027 [2] - The pre-NDA communication for 99mTc-GSA is in progress, although specific details were not provided [2] Group 2: Market Strategy - The company is committed to actively promoting the research and development progress to expedite the market launch of its products [2]

Core Viewpoint - The company is actively preparing for the NDA submission of Fluorine-18 labeled Somatostatin Injection, with an expected submission in the first half of 2026, although the approval timeline remains uncertain [1] Group 1 - The company is currently working on the NDA submission preparations for the Fluorine-18 Somatostatin Injection [1] - The expected timeline for NDA submission is the first half of 2026 [1] - The approval timeline is uncertain and will depend on regulatory requirements [1]

Group 1 - The company, Yantai Dongcheng Pharmaceutical Group Co., Ltd., has received a production license for radioactive drugs for its subsidiary, Yantai Lanacheng Biotechnology Co., Ltd. [1] - The production license is specifically for the radiopharmaceutical fluorine-18 labeled peptide injection, which is intended for product registration application use only [1] - The license is valid until November 25, 2030, and the production will take place at Nanjing Jiangyuan Andike Positron Research and Development Co., Ltd. [1] Group 2 - The company anticipates that the acquisition of the production license will not have a significant impact on its current performance, as commercial production can only commence after obtaining the drug marketing approval number [1] - The pharmaceutical industry is characterized by high technology, high risk, and high added value, making drug sales susceptible to changes in industry policies and market conditions [2]

Policy Developments - The National Healthcare Security Administration announced five typical cases of fraud involving maternity insurance funds, urging insured units and individuals to participate legally and provide accurate application materials to safeguard the fund [1] Drug and Device Approvals - Dongcheng Pharmaceutical's subsidiary received a production license for radioactive drugs, with expectations that it will not significantly impact current performance until commercial production is approved [1] - Jianyou Co., Ltd. received FDA approval for its propofol emulsion injection, with an investment of approximately RMB 73.66 million in R&D, and plans to launch the product in the U.S. soon [2] - Aihong Pharmaceutical presented clinical trial data for APL-1401 at the European Colorectal Congress, focusing on treating moderate to severe ulcerative colitis [6] - Fosun Pharma's subsidiary received approval for clinical trials of FXS887, an innovative drug for treating advanced malignant solid tumors [7] - Xinlitai received approval for clinical trials of SAL0140, a novel drug for chronic kidney disease, which could provide new treatment options if successful [8] Capital Market Activities - Lexin Medical announced that its controlling shareholder, Pan Weichao, has released the pledge on 18.71 million shares, which is 28.01% of his holdings and 8.56% of the total share capital [3] - Berry Genomics reported a decrease in the shareholding ratio of its controlling shareholder, Gao Yang, to 6.90% due to stock pledge defaults, with no significant adverse impact on the company's operations [4] - Tailong Pharmaceutical is planning a major matter that may lead to a change in control, with stock suspension expected to last no more than three trading days [5] Strategic Collaborations - JD Health and Boehringer Ingelheim Animal Health signed a strategic cooperation agreement to enhance the quality development of the domestic pet health industry through resource integration and complementary advantages [10] Regulatory Actions - Guizhou Bai Ling's actual controller, Jiang Wei, is under investigation by the China Securities Regulatory Commission for insider trading and other violations, which does not affect the company's daily operations [11]

Core Viewpoint - Dongcheng Pharmaceutical (002675) announced that its subsidiary, Lanacheng, has received a production license for radioactive drugs from the Shandong Provincial Drug Administration, which is expected to have no significant impact on the company's current performance [1] Group 1 - Lanacheng has obtained the production license for radioactive drugs, allowing it to proceed with commercial production once it receives the marketing approval for Fluorine-18 labeled somatostatin analog injection [1]

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) announced that its subsidiary, Yantai Lanacheng Biotechnology Co., Ltd. (referred to as "Lanacheng"), has received the "Production License for Radioactive Drugs" from the Shandong Provincial Drug Administration. This license is expected to have no significant impact on the company's current performance, and the fluorine-18 labeled peptide injection will be commercially produced after obtaining the drug listing approval number [1]. Group 1 - Dongcheng Pharmaceutical's subsidiary Lanacheng has received a production license for radioactive drugs [1] - The production license is anticipated to not significantly affect the current performance of Dongcheng Pharmaceutical [1] - The fluorine-18 labeled peptide injection will be available for commercial production following the drug listing approval [1]